McKesson acquires Precision Medicine Group
Analysis based on 16 articles · First reported Aug 25, 2026 · Last updated Aug 25, 2026
The acquisition is expected to strengthen McKesson's position in the high-growth oncology and specialty care market, potentially boosting its revenue and margins. McKesson's stock rose 1.2% on the news, reflecting positive market sentiment, while the deal may also benefit Precision Medicine Group's clients and employees through expanded resources.
McKesson Corporation announced a definitive agreement to acquire Precision Medicine Group, a global provider of clinical research and biopharma commercialization services, for approximately $2.25 billion. The acquisition will enhance McKesson's clinical research and commercialization capabilities, strengthen clinical trial execution, and broaden its clinical service offerings. Precision Medicine Group will report within McKesson's Oncology & Multispecialty segment upon closing. The deal is subject to customary closing conditions, including regulatory clearances, and no closing date has been disclosed. McKesson's CEO Brian Tyler stated that the acquisition advances the company's oncology and multispecialty strategy, while Precision Medicine Group CEO Margaret Keegan highlighted the opportunity to extend clinical and commercial expertise. McKesson's shares gained 1.2% in Tuesday morning trading. The acquisition aligns with McKesson's strategy of investing in faster-growing areas like oncology and specialty care, following its recent purchases of controlling stakes in Core42 and PRISM Vision Holdings, and its plan to divest a minority stake in its medical-surgical solutions unit to Apollo Funds.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard